Navigation Links
Late-stage ovarian cancer shows promise in 2-drug phase I trial
Date:6/10/2010

INDIANAPOLIS -- The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of treatment. One patient experienced complete resolution of tumor tissue for a period of time.

Advanced ovarian cancer is often diagnosed too late for treatment to be effective. Patients are often told they have virtually no chance of recovery and only months to live.

Women participating in the study were between 51 and 71, and had previously exhausted all approved treatments for ovarian cancer. They enrolled in an Indiana University Melvin and Bren Simon Cancer Center clinical trial designed to increase their sensitivity to the commonly prescribed ovarian cancer drug, platinum-based carboplatin.

Women with ovarian cancer usually survive less than one year after they become resistant to carboplatin and their cancer recurs, said co-principal investigator Daniela Matei, M.D., an associate professor of medicine at the Indiana University School of Medicine. Matei led the clinical portion of the trial.

"Carboplatin is the most efficient drug therapy for ovarian cancer," Matei said. "Unfortunately, patients with recurrent disease become resistant to the drug after one or two rounds."

Decitabine was first used to treat the study patients intravenously daily for five days followed on the eighth day with carboplatin. After a month, the regimen begins again.

Six months after the trial began, four of the patients had no disease progression. At eight-and-a-half months, seven patients were alive (and at press time, still alive). Cancerous tissue in one of the patients shrank completely.

Adverse reactions to the treatment regiments were mild, including nausea, fatigu
'/>"/>

Contact: Mary L. Hardin
mhardin@iupui.edu
317-274-7722
Indiana University School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Late-stage ovarian cancer shows promise in two-drug phase I trial
2. Cancer Drug Safe for Late-Stage Pelvic Disease
3. Late-stage melanoma results in economic burden
4. New treatment regimen shown effective against advanced ovarian cancer
5. Early Detection of Ovarian Cancer Moves Closer
6. CA-125 change over time shows promise as screening tool for early detection of ovarian cancer
7. PMH cancer researchers link ovarian hormone to breast stem cells growth
8. Study Makes Strides in Understanding Ovarian Cancer
9. Researchers identify a new breast and ovarian cancer susceptibility gene
10. Ovarian cancer study offers vital clues for new therapies
11. Only women with Western Swedish breast cancer gene run higher risk of ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... On October 22, CBS will air an ... both fictional and real. The Charles E Holman ... to advocacy and philanthropy in the battle against Morgellons ... to impart truth and clarity about this misunderstood and ... misconceptions about Morgellons Disease (MD) and most ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Shriners Hospitals ... that will change the current location of Shriners Hospitals ... South Limestone across from the University of Kentucky Albert ... state-of-the-art ambulatory care center, owned and operated by Shriners ... orthopaedic needs of children and their families well into ...
(Date:10/22/2014)... Washington, D.C. (PRWEB) October 22, 2014 With ... November, a national survey by the American Institutes for Research ... they know how to use health insurance, but 42 percent ... review a plan’s details before signing up for coverage. , ... literacy, with only 20 percent able to calculate correctly how ...
(Date:10/22/2014)... October 22, 2014 Healthcare professionals ... their continuing education at home or on-the-go via ... to 20 brand new, premium Seminar-on-Demand CE courses. ... of over 2,000 hours of CE ... their educational experience. With such a diverse library, ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2
... Nov. 13 Researchers have,long been examining the link ... 2,000 years ago, it was Hippocrates who suggested that,removing ... that the,mouth is connected to the rest of the ... to diagnose, make a prognosis, treat and intervene on ...
... ECONOMIC STATUS TIED TO LUNG FUNCTION , New research ... an important determinant of lung function. After reviewing 20 ... and lung function in children and adults, researchers from ... Lake City found a significant negative correlation between the ...
... Oracle and DrugLogic solutions to deliver a comprehensive drug ... safety and ... OPENWORLD 2007 -- Tata,Consultancy Services (TCS), (BSE: TCS.BO, NSE: ... firm and Certified Advantage,Partner in the Oracle PartnerNetwork, announced ...
... 13 ISTO Technologies, Inc. a privately,held orthobiologics ... Vice President of Sales. ISTO President and ... a proven talent from the medical device industry, ... joining ISTO,Blake was a Regional Sales Manager with ...
... DUBLIN, Ohio, Nov. 13 Cardinal Health today,announced ... deliver,Web-based technology that helps eligible health care facilities ... the federal 340B,Drug Pricing Program. The 340B ... eligible,hospitals and other federally qualified health care facilities ...
... for certain meds , , TUESDAY, Nov. 13 (HealthDay ... Drug Administration are meeting Wednesday to hear arguments on ... directly provide consumers with certain drugs that now require ... ahead, it would create a new class of drugs ...
Cached Medicine News:Health News:PDA Stresses Link Between Oral Health and Overall Health 2Health News:PDA Stresses Link Between Oral Health and Overall Health 3Health News:TCS, Oracle and DrugLogic Prescribe Safety in a Capsule(TM) 2Health News:TCS, Oracle and DrugLogic Prescribe Safety in a Capsule(TM) 3Health News:TCS, Oracle and DrugLogic Prescribe Safety in a Capsule(TM) 4Health News:ISTO Technologies, Inc. Appoints Blake Miles as Vice President of Sales 2Health News:Cardinal Health, Sentry Data Systems Introduce New Technology to Help Health Care Providers More Cost-Efficiently Care for Underserved 2Health News:Cardinal Health, Sentry Data Systems Introduce New Technology to Help Health Care Providers More Cost-Efficiently Care for Underserved 3Health News:Cardinal Health, Sentry Data Systems Introduce New Technology to Help Health Care Providers More Cost-Efficiently Care for Underserved 4Health News:FDA Mulls Direct Pharmacist-to-Patient Drug Sales 2Health News:FDA Mulls Direct Pharmacist-to-Patient Drug Sales 3Health News:FDA Mulls Direct Pharmacist-to-Patient Drug Sales 4
(Date:10/22/2014)... 22, 2014 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of ... clinical results from its Phase IIa clinical trial ... to treat type 1 diabetes. The trial was conducted ... under a U.S. Food and Drug Administration (FDA) ...
(Date:10/22/2014)... Oct. 22, 2014   Surefire Medical , Inc., ... designed to maximize targeted delivery of embolization agents in ... that oncologist John R. Daniels , MD of ... and surgical oncologist Steven C. Katz , MD ... Company,s Scientific Advisory Board (SAB).    "The ...
(Date:10/22/2014)... -- Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in developing ... for cancer, is designed for injection into solid tumors ... focus is on melanoma, breast cancer and cancers of ... PV-10 as a therapy for metastatic melanoma, and of ... psoriasis. This summer, the Company signed ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... are offered as 1-piece or modular, in ... instruments may be customized with handles of ... insulation and flush ports. Many standard patterns ... may affect delivery times. , Please ...
Medicine Products: